Posted by Michael Wonder on 05 Aug 2020
Leo Pharma announces US FDA fast track designation for delgocitinib cream for the treatment of adults with moderate to severe chronic hand eczema
4 August 2020 - Leo Pharma today announced that delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted fast track designation by the US FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema.
There are currently no treatment options available in the US specifically developed and approved for the treatment of chronic hand eczema.
Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.
